Document:

Exhibit 10.1

 

Confidential

 

FORM OF SUBSCRIPTION AGREEMENT

 

Vector Acquisition Corporation

One Market Street

Steuart Tower, 23rd Floor

San Francisco, California 94105

 

Ladies and Gentlemen:

 

This Subscription Agreement
(this “Subscription Agreement”) is being entered into as of the date set forth on the signature page hereto,
by and among Vector Acquisition Corporation, a Cayman Islands exempted company (“VACQ”), and the undersigned
Investor (the “Investor”), in connection with the Agreement and Plan of Merger, dated as of the date hereof
(as may be amended, supplemented or otherwise modified from time to time, the “Merger Agreement”), by and among
VACQ, Rocket Lab USA, Inc., a Delaware corporation (the “Company”), and Prestige USA Merger Sub, Inc. a Delaware
corporation and a direct, wholly-owned subsidiary of the Company (“Merger Sub”), pursuant to which, among other
things, (a) Merger Sub will merge with and into VACQ, with VACQ as the surviving corporation of such merger, and (b) the Company
will merge with and into VACQ, with VACQ as the surviving corporation of such merger (the “Surviving Corporation”)
(such mergers, the “Transaction”). Prior to the closing of the Transaction
(and as more fully described in the Merger Agreement), VACQ will domesticate as a Delaware corporation in accordance with Section
388 of the General Corporation Law of the State of Delaware and Part XII of the Cayman Islands Companies Law (2020 Revision) (the
“Domestication”). In connection with the Transaction, VACQ is seeking commitments from interested investors
to purchase, following the Domestication and prior to the closing of the Transaction, shares of VACQ’s common stock, par
value $0.0001 per share (the “Common Stock” and such shares to be purchased, the “Shares”),
in a private placement for a purchase price of $10.00 per share (the “Price Per Share”). The aggregate
purchase price to be paid by the Investor for the subscribed Shares (as set forth on the signature page hereto) is referred to
herein as the “Subscription Amount.” Substantially concurrently with the execution of this Subscription Agreement,
VACQ is entering into separate subscription agreements with certain investors (the “Other Investors,” and such
other subscription agreements, the “Other Subscription Agreements”) acquiring Shares at the same Price Per Share.

 

In connection therewith,
and in consideration of the foregoing and the mutual representations, warranties and covenants, and subject to the conditions,
set forth herein, and intending to be legally bound hereby, each of the Investor and VACQ acknowledges and agrees as follows:

 

1. Subscription.
The Investor hereby subscribes for and agrees to purchase from VACQ, and VACQ agrees to issue and sell to the Investor, the number
of Shares set forth on the signature page of this Subscription Agreement on the terms and subject to the conditions provided for
herein. The Investor acknowledges and agrees that, as a result of the Domestication, the Shares that will be issued pursuant hereto
shall be shares of Common Stock in a Delaware corporation (and not, for the avoidance of doubt, ordinary shares in a Cayman Islands
exempted company).

 

2. Closing.
The closing of the sale of the Shares contemplated hereby (the “Closing”) shall occur on the date of and substantially
concurrently with and conditioned upon the closing of the Transaction and satisfaction of the other conditions set forth in Section
3 hereof (such date, the “Closing Date”). At least five (5) business days prior to the anticipated Closing
Date, VACQ shall deliver a written notice (the “Closing Notice”) to the Investor, specifying (a) the anticipated
Closing Date and (b) wire instructions for the account(s) into which the Investor shall fund the Subscription Amount. [On the
Closing Date, the Investor shall deliver (i) the Subscription Amount by wire transfer of United States dollars in immediately
available funds to the account(s) specified by VACQ in the Closing Notice (which account shall not be an escrow account) and (ii)
any other information that is reasonably requested in the Closing Notice in order for VACQ to issue the subscribed Shares, including,
without limitation, the legal name of the person in whose name such Shares are to be issued and a duly executed Internal Revenue
Service Form W-9 or W-8, as applicable. On the Closing Date, VACQ shall deliver to the Investor the number of Shares set forth
on the signature page to this Subscription Agreement in book-entry form, free and clear of any liens or other restrictions whatsoever
(other than those set forth in this Subscription Agreement, arising under any written agreement to which the Investor is a party
or arising under applicable securities laws), in the name of the Investor (or its nominee in accordance with its delivery instructions)
by causing such Shares to be registered on VACQ’s share register, and the Subscription Amount shall be released from escrow
automatically and without further action by the VACQ or the Investor.]1 [No later than two (2) business days prior
to the Closing Date, the Investor shall provide VACQ information that is reasonably requested in the Closing Notice in order for
VACQ to issue the Shares, including, without limitation, the name of the person in whose name such Shares are to be issued (or
a nominee as indicated by the Investor) and a duly executed Internal Revenue Service Form W-9 or W-8, as applicable. On the Closing
Date, (x) promptly following receipt of evidence of issuance of the Shares as set forth in clause (y). the Investor shall deliver
the Subscription Amount by wire transfer of United States dollars in immediately available funds to the account(s) specified by
VACQ in the Closing Notice (which shall not be escrow accounts) and (y) VACQ shall deliver to the Investor the Shares in book-entry
form, free and clear of any liens or other restrictions whatsoever (other than those set forth in this Subscription Agreement,
arising under any written agreement to which the Investor is a party or arising under applicable securities laws), in the name
of the Investor (or its nominee in accordance with its delivery instructions) by causing such Shares to be registered on VACQ’s
share register and will provide the Investor evidence of such issuance from VACQ’s transfer agent.]2 In the event
the closing of the Transaction does not occur within one (1) business day of the Closing Date specified in the Closing Notice,
unless otherwise instructed by the Investor, VACQ shall promptly (but not later than one (1) business day thereafter) return the
Subscription Amount to the Investor by wire transfer of U.S. dollars in immediately available funds to the account specified by
the Investor without any deduction for or on account of any tax, withholding, charges, or set-off, and any book entries shall
be deemed cancelled. For purposes of this Subscription Agreement, “business day” shall mean a day, other than a Saturday
or Sunday, on which commercial banks in New York, New York and San Francisco, California are open for the general transaction
of business.

 

 

 

 

	1	For non-mutual fund investors.

	2	For mutual fund investors.

 

     

    Confidential

    

 

3. Closing
Conditions. 

 

a. The
obligations of the parties hereto to consummate the purchase and sale of the Shares pursuant to this Subscription Agreement is
subject to the following conditions:

 

(i) no
suspension of the qualification of the Shares for offering or sale or trading in any jurisdiction, or initiation or threatening
of any proceedings for any of such purposes, shall have occurred;

 

(ii) no
applicable governmental authority shall have enacted, issued, promulgated, enforced or entered any judgment, order, law, rule or
regulation which is then in effect and has the effect of making the consummation of the transactions contemplated hereby illegal
or otherwise restraining or prohibiting consummation of the transactions contemplated hereby; and

 

(iii) all
conditions precedent to the closing of the Transaction under the Merger Agreement shall have been satisfied or waived (as determined
by the parties to the Merger Agreement and other than those conditions under the Merger Agreement which, by their nature, are to
be fulfilled at the closing of the Transaction, including to the extent that any such condition is dependent upon the consummation
of the purchase and sale of the Shares pursuant to this Subscription Agreement, but subject to the satisfaction or waiver of such
conditions at the closing of the Transaction) and the closing of the Transaction shall occur, in accordance with the terms of the
Merger Agreement, on the Closing Date, substantially concurrently with the Closing.

 

b. The
obligation of VACQ to consummate the issuance and sale of the Shares pursuant to this Subscription Agreement shall be subject to
the conditions that (i) all representations and warranties of the Investor contained in this Subscription Agreement be true and
correct in all material respects when made, and be true and correct in all material respects on and as of the Closing Date (unless
they specifically speak as of an earlier date in which case they shall be true and correct in all material respects as of such
date), and the Investor hereby acknowledges that the consummation of the Closing shall constitute a reaffirmation by the Investor
of each of the representations and warranties of the Investor contained in this Subscription Agreement as of the Closing Date;
and (ii) all obligations, covenants and agreements of the Investor required to be performed by it at or prior to the Closing Date
shall have been performed in all material respects.

 

    2

    Confidential

    

 

c. The
obligation of the Investor to consummate the purchase of the Shares pursuant to this Subscription Agreement shall be subject to
the conditions that (i) all representations and warranties of VACQ contained in this Subscription Agreement shall (x) be true and
correct in all material respects (other than representations and warranties that are qualified as to materiality or VACQ Material
Adverse Effect (as defined herein), which representations and warranties shall be true and correct in all respects) when made,
and (y) be true and correct in all material respects on and as of the Closing Date (other than (1) representations and warranties
that are qualified as to materiality or VACQ Material Adverse Effect, which representations and warranties shall be true and correct
in all respects on and as of the Closing Date, and (2) those representations expressly speak as of an earlier date, which shall
be true and correct in all material respects (or, if qualified by materiality or VACQ Material Adverse Effect, in all respects)
as of such earlier date), and VACQ hereby acknowledges that the consummation of the Closing shall constitute a reaffirmation by
VACQ of each of the representations and warranties of VACQ contained in this Subscription Agreement as of the Closing Date; (ii)
all obligations, covenants and agreements of VACQ required to be performed by it at or prior to the Closing Date shall have been
performed in all material respects; and (iii) no amendment, waiver or modification of the Merger Agreement (as the same exists
on the date hereof as provided to the Investor) shall have occurred that materially and adversely affects the Investor’s
economic benefits under this Subscription Agreement.

 

4. Further
Assurances. At the Closing, the parties hereto shall execute and deliver such additional documents and take such additional
actions as the parties reasonably may deem to be practical and necessary in order to consummate the subscription as contemplated
by this Subscription Agreement.

 

5. VACQ
Representations and Warranties. VACQ represents and warrants to the Investor that:

 

a. VACQ
is as of the date of this Agreement duly incorporated, validly existing and in good standing in the Cayman Islands (to the extent
such concept exists in such jurisdiction) and will be duly incorporated, validly existing and in good standing under the laws of
the State of Delaware as of the Closing Date. VACQ has all power (corporate or otherwise) and authority to own, lease and operate
its properties and conduct its business as presently conducted and to enter into, deliver and perform its obligations under this
Subscription Agreement.

 

b. As
of the Closing Date, the Shares will be duly authorized and, when issued and delivered to the Investor in exchange for the Subscription
Amount in accordance with the terms of this Subscription Agreement, the Shares will be validly issued, fully paid and non-assessable
and will not have been issued in violation of any preemptive or similar rights created under VACQ’s organizational documents
(as amended as of the Closing Date) or under the General Corporation Law of the State of Delaware.

 

c. This
Subscription Agreement and the Merger Agreement (collectively, the “Transaction Documents”) have been duly authorized,
executed and delivered by VACQ and, assuming that the Transaction Documents constitute the valid and binding agreement of the other
parties thereto, the Transaction Documents are valid and binding obligations of VACQ, enforceable against VACQ in accordance with
their respective terms, except as may be limited or otherwise affected by (i) bankruptcy, insolvency, fraudulent conveyance, reorganization,
moratorium or other laws relating to or affecting the rights of creditors generally, or (ii) principles of equity, whether considered
at law or equity.

 

d. The
execution and delivery of, and the performance of the transactions contemplated by this Subscription Agreement and the other Transaction
Documents, including the issuance and sale of the Shares and the compliance by VACQ with all of the provisions of this Subscription
Agreement and the consummation of the transactions contemplated herein, will not (i) conflict with or result in a breach or violation
of any of the terms or provisions of, or constitute a default under, or result in the creation or imposition of any lien, charge
or encumbrance upon any of the property or assets of VACQ or any of its subsidiaries pursuant to the terms of any indenture, mortgage,
deed of trust, loan agreement, lease, license or other agreement or instrument to which VACQ or any of its subsidiaries is a party
or by which VACQ or any of its subsidiaries is bound or to which any of the property or assets of VACQ is subject that would reasonably
be expected to have, individually or in the aggregate, a material adverse effect on the business, properties, financial condition,
stockholders’ equity or results of operations of VACQ and its subsidiaries, individually or taken as a whole or prevents,
materially impairs the validity of the Shares or the legal authority of VACQ to comply in all material respects with the terms
of this Subscription Agreement (a “VACQ Material Adverse Effect”); (ii) result in any violation of the provisions of
the organizational documents of VACQ or any of its subsidiaries; or (iii) result in any violation of any statute or any judgment,
order, rule or regulation of any court or governmental agency or body, domestic or foreign, having jurisdiction over VACQ or any
of its subsidiaries or any of their respective properties that would reasonably be expected to have, individually or in the aggregate,
a VACQ Material Adverse Effect.

 

    3

    Confidential

    

 

e. As
of their respective dates, all reports (the “SEC Reports”) required to be filed by VACQ with the U.S. Securities
and Exchange Commission (the “SEC”) complied in all material respects with the applicable requirements of the
Securities Act of 1933, as amended (the “Securities Act”), and/or the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), and the rules and regulations of the SEC promulgated thereunder, and none of the SEC Reports,
when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein
or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.
The financial statements of VACQ included in the SEC Reports comply in all material respects with applicable accounting requirements
and the rules and regulations of the SEC with respect thereto as in effect at the time of filing and fairly present in all material
respects the financial position of VACQ as of and for the dates thereof and the results of operations and cash flows for the periods
then ended, subject, in the case of unaudited statements, to normal, year-end audit adjustments. VACQ has timely filed with the
SEC each SEC Report that VACQ was required to file with the SEC. There are no outstanding or unresolved comments in comment letters
received by VACQ from the staff of the Division of Corporation Finance of the SEC with respect to any of the SEC Reports.

 

f. Except
for such matters as have not had and would not be reasonably expected to have, individually or in the aggregate, a VACQ Material
Adverse Effect, as of the date hereof, there is no (i) action, suit, claim or other proceeding, in each case by or before any governmental
authority pending, or, to the knowledge of VACQ, threatened against VACQ or (ii) judgment, decree, injunction, ruling or order
of any governmental authority or arbitrator outstanding against VACQ.

 

g. As
of the date of this Subscription Agreement, the authorized capital stock of VACQ consists of (i) 1,000,000 preference shares
of VACQ, par value $0.0001 per share (the “Preference Shares”), of which no Preference Shares are issued and
outstanding; (ii) 450,000,000 Class A ordinary shares, par value $0.0001 per share (the “Class A Ordinary Shares”),
of which 32,000,000 Class A Ordinary Shares are issued and outstanding; (iii) 50,000,000 Class B ordinary shares of VACQ, par value
$0.0001 per share (the “Class B Ordinary Shares”), of which 8,000,000 Class B Ordinary Shares are issued and
outstanding; (iv) 5,600,000 warrants to purchase one Class A Ordinary Share (the “Cayman Private Placement Warrants”),
all of which are outstanding; and (v) 10,666,667 warrants to purchase one Class A Ordinary Share (the “Cayman Public Warrants,”
collectively with the Private Placement Warrants, the “ Cayman Warrants”), all of which are outstanding. All
outstanding Class A Ordinary Shares and Class B Ordinary Shares have been duly authorized, validly issued, fully paid and are not
subject to preemptive or similar rights. All Class A Ordinary Shares issuable upon exercise
of the Cayman Warrants have been duly authorized and reserved for issuance and, upon issuance in accordance with the terms of the
Cayman Warrants, will be validly issued, fully paid and not subject to preemptive or similar rights. Immediately following the
Domestication and prior to the consummation of the Transaction, the capital stock of VACQ will consist of (i) no issued or outstanding
preferred stock; (ii) Common Stock of VACQ, of which 40,000,000 shares of Common Stock will be issued and outstanding; (iii) 5,600,000
warrants to purchase one share of Common Stock (the “US Private Placement Warrants”), all of which will be outstanding;
and (iv) 10,666,667 warrants to purchase one share of Common Stock (the “US Public Warrants,” collectively with the
US Private Placement Warrants, the “US Warrants,” and collectively with the Cayman Warrants, the “Warrants”),
all of which will be outstanding. Except as set forth above and pursuant to the Domestication, the Other Subscription Agreements,
the Merger Agreement and the other agreements and arrangements referred to in the Merger Agreement, as of the date hereof, there
are no outstanding, and between the date hereof and the Closing, VACQ will not issue, sell or cause to be outstanding any (A) shares,
equity interests or voting securities of VACQ, (B) securities of VACQ convertible into or exchangeable for shares or other equity
interests or voting securities of VACQ, (C) options, warrants or other rights (including preemptive rights) or agreements, arrangements
or commitments of any character, whether or not contingent, of VACQ to subscribe for, purchase or acquire from any individual,
entity or other person, and no obligation of VACQ to issue, any shares or other equity interests or voting securities of VACQ,
or any securities convertible into or exchangeable or exercisable for such shares or other equity interests or voting securities,
(D) equity equivalents or other similar rights of or with respect to VACQ, or (E) obligations of VACQ to repurchase, redeem or
otherwise acquire any of the foregoing securities, shares, options, equity equivalents, interests or rights (other than as provided
in VACQ’s organizational documents). As of the date hereof, VACQ has no subsidiaries other than Merger Sub and does not own,
directly or indirectly, interests or investments (whether equity or debt) in any person, whether incorporated or unincorporated.
There are no shareholder agreements, voting trusts or other agreements or understandings to which VACQ is a party or by which it
is bound relating to the voting of any securities of VACQ, other than (1) as set forth in the SEC Reports and (2) as
contemplated by the Merger Agreement.

 

    4

    Confidential

    

 

h. As
of the date hereof, the issued and outstanding Class A Ordinary Shares are, and as of the Closing Date, the issued and outstanding
Common Stock will be, registered pursuant to Section 12(b) of the Exchange Act, and the Class A Ordinary Shares are, and the
Common Stock will be, listed for trading on The Nasdaq Stock Market (“Nasdaq”). There is no suit, action, proceeding
or investigation pending or, to the knowledge of VACQ, threatened against VACQ by Nasdaq or the SEC with respect to any intention
by such entity to deregister such shares or prohibit or terminate the listing of the Class A Ordinary Shares or Common Stock on
Nasdaq. VACQ has taken no action that is designed to terminate the registration of such shares under the Exchange Act.

 

i. VACQ
is not, and immediately after receipt of payment for the Shares will not be, an “investment company” within the meaning
of the Investment Company Act of 1940, as amended.

 

j. The
Other Subscription Agreements reflect the same Price Per Share and other terms with respect to the purchase of the Shares that
are not more favorable to the Other Investors thereunder than the terms of this Subscription Agreement, other than terms particular
to the regulatory requirements of such Other Investor or its affiliates or related funds.

 

6. Investor
Representations and Warranties. The Investor represents and warrants to VACQ that:

 

a. The
Investor (i) is a “qualified institutional buyer” (as defined in Rule 144A under the Securities Act) or an institutional
“accredited investor” (within the meaning of Rule 501(a) under the Securities Act), in each case, satisfying the applicable
requirements set forth on Schedule A, (ii) is acquiring the Shares only for the Investor’s own account and not for
the account of others, or if the Investor is subscribing for the Shares as a fiduciary or agent for one or more investor accounts,
the Investor has full investment discretion with respect to each such account, and the full power and authority to make the acknowledgements,
representations and agreements herein on behalf of each owner of each such account, and (iii) is not acquiring the Shares with
a view to, or for offer or sale in connection with, any distribution thereof in violation of the Securities Act (and shall provide
the requested information set forth on Schedule A). The Investor is not an entity formed for the specific purpose of acquiring
the Shares. The representations and warranties set forth on Schedule B are true and correct as of the date of this Subscription
Agreement and will be true and correct as of the Closing Date. Furthermore, the Investor agrees that its signature to this Subscription
Agreement shall constitute a signature on Schedule B hereto regardless of whether the Investor returns a signed copy of
Schedule B.

 

b. The
Investor acknowledges and agrees that the Shares are being offered in a transaction not involving any public offering within the
meaning of the Securities Act and that the Shares have not been registered under the Securities Act. The Investor acknowledges
and agrees that the Shares may not be offered, resold, transferred, pledged (other than in connection with ordinary course prime
brokerage relationships) or otherwise disposed of by the Investor absent an effective registration statement under the Securities
Act except (i) to VACQ or a subsidiary thereof, (ii) to non-U.S. persons pursuant to offers and sales that occur outside the United
States within the meaning of Regulation S under the Securities Act or (iii) pursuant to another applicable exemption from the registration
requirements of the Securities Act (including, without limitation, a private resale pursuant to the so-called Section 4(a)(1 1⁄2))
exemption, and, in each of clauses (i) and (iii) in accordance with any applicable securities laws of the states and other jurisdictions
of the United States, and that the applicable records of VACQ and its transfer agent wherein the book entries recording ownership
of the Shares (and, if applicable, any certificates representing the Shares) shall contain a restrictive legend to such effect.
The Investor acknowledges and agrees that the Shares will be subject to transfer restrictions and, as a result of these transfer
restrictions, the Investor may not be able to readily offer, resell, transfer, pledge or otherwise dispose of the Shares and may
be required to bear the financial risk of an investment in the Shares for an indefinite period of time. The Investor acknowledges
and agrees that the Investor has been advised to consult with its legal counsel and tax and accounting advisors prior to making
any offer, resale, transfer, pledge or disposition of any of the Shares.

 

    5

    Confidential

    

 

c. The
Investor acknowledges and agrees that the Investor is purchasing the Shares from VACQ and that VACQ will become a Delaware corporation
on or before the Closing Date. The Investor further acknowledges that there have been no representations, warranties, covenants
and agreements made to the Investor by or on behalf of VACQ, the Company, any of their respective affiliates or any control persons,
direct or indirect equityholders, officers, managers, directors, employees, consultants, partners, agents or representatives of
any of the foregoing or any other person or entity, expressly or by implication, other than those representations, warranties,
covenants and agreements of VACQ expressly set forth in this Subscription Agreement.

 

d. The
Investor acknowledges and agrees that the Investor has received such information as the Investor deems necessary in order to make
an investment decision with respect to the Shares, including, with respect to VACQ, the Transaction and the business of the Company
and its subsidiaries. Without limiting the generality of the foregoing, the Investor acknowledges that he, she or it has had the
opportunity to review VACQ’s filings with the SEC. The Investor acknowledges and agrees that the Investor and the Investor’s
professional advisor(s), if any, have had the full opportunity to ask such questions, receive such answers and obtain such information
as the Investor and such Investor’s professional advisor(s), if any, have deemed necessary to make an investment decision
with respect to the Shares. The Investor further acknowledges that the information provided to the Investor may change and VACQ
is under no obligation to inform the Investor regarding any such changes.

 

e. The
Investor became aware of this offering of the Shares solely by means of direct contact between the Investor and VACQ, the Company
or a representative of VACQ or the Company, and the Shares were offered to the Investor solely by direct contact between the Investor
and VACQ, the Company or a representative of VACQ or the Company. The Investor did not become aware of this offering of the Shares,
nor were the Shares offered to the Investor, by any other means. The Investor acknowledges that the Shares (i) were not offered
by any form of general solicitation or general advertising and (ii) are not being offered in a manner involving a public offering
under, or in a distribution in violation of, the Securities Act or any state securities laws. The Investor acknowledges that it
is not relying upon, and has not relied upon, any statement, representation or warranty made by any person, firm or corporation
(including, without limitation, VACQ, the Company, the Placement Agents, any of their respective affiliates or any control persons,
direct or indirect equityholders, officers, managers, directors, employees, consultants, partners, agents or representatives of
any of the foregoing), other than the representations and warranties of VACQ contained in of this Subscription Agreement, in making
its investment or decision to invest in VACQ.

 

f. The
Investor acknowledges that it is aware that there are substantial risks incident to the purchase and ownership of the Shares, including
those set forth in VACQ’s filings with the SEC. The Investor has such knowledge and experience in financial and business
matters as to be capable of evaluating the merits and risks of an investment in the Shares, and the Investor has sought such accounting,
legal and tax advice as the Investor has considered necessary to make an informed investment decision.

 

g. Alone,
or together with any professional advisor(s), the Investor has adequately analyzed and fully considered the risks of an investment
in the Shares and determined that the Shares are a suitable investment for the Investor and that the Investor is able at this time
and in the foreseeable future to bear the economic risk of a total loss of the Investor’s investment in VACQ. The Investor
acknowledges specifically that a possibility of total loss exists. The Investor is able to sustain a complete loss on its investment
in the Shares, has no need for liquidity with respect to its investment in the Shares and has no reason to anticipate any change
in circumstances, financial or otherwise, which may cause or require any sale or distribution of all or any part of the Shares.

 

h. In
making its decision to purchase the Shares, the Investor has relied solely upon independent investigation made by the Investor.
Without limiting the generality of the foregoing, the Investor has not relied on any statements or other information provided by
or on behalf of either Placement Agent or any of their respective affiliates or any control persons, officers, directors, employees,
partners, agents or representatives of any of the foregoing concerning VACQ, the Company, the Transaction, the Merger Agreement,
this Subscription Agreement or the transactions contemplated hereby or thereby, the Shares or the offer and sale of the Shares.

 

    6

    Confidential

    

 

i. The
Investor acknowledges and agrees that no federal or state agency has passed upon or endorsed the merits of the offering of the
Shares or made any findings or determination as to the fairness of this investment.

 

j. The
Investor has been duly formed or incorporated and is validly existing and is in good standing under the laws of its jurisdiction
of formation or incorporation, with power and authority to enter into, deliver and perform its obligations under this Subscription
Agreement.

 

k. The
execution, delivery and performance by the Investor of this Subscription Agreement are within the powers of the Investor, have
been duly authorized and will not constitute or result in a breach or default under or conflict with any order, ruling or regulation
of any court or other tribunal or of any governmental commission or agency, or any agreement or other undertaking, to which the
Investor is a party or by which the Investor is bound, and, if the Investor is not an individual, will not violate any provisions
of the Investor’s organizational documents, including, without limitation, its incorporation or formation papers, bylaws,
indenture of trust or partnership or operating agreement, as may be applicable. The signature on this Subscription Agreement is
genuine, and the signatory has been duly authorized to execute the same and, assuming that this Subscription Agreement constitutes
the valid and binding agreement of VACQ, this Subscription Agreement constitutes a legal, valid and binding obligation of the Investor,
enforceable against the Investor in accordance with its terms except as may be limited or otherwise affected by (i) bankruptcy,
insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the rights of creditors generally,
and (ii) principles of equity, whether considered at law or equity.

 

l. The
Investor is not (i) a person or entity named on the List of Specially Designated Nationals and Blocked Persons administered by
the U.S. Treasury Department’s Office of Foreign Assets Control (“OFAC”) or in any Executive Order issued
by the President of the United States and administered by OFAC (“OFAC List”), or a person or entity prohibited
by any OFAC sanctions program, (ii) owned, directly or indirectly, or controlled by, or acting on behalf of, one or more persons
that are named on the OFAC List, (iii) organized, incorporated, established, located, resident or born in, or a citizen, national
or the government, including any political subdivision, agency or instrumentality thereof, of, Cuba, Iran, North Korea, Syria,
the Crimea region of Ukraine or any other country or territory embargoed or subject to substantial trade restrictions by the United
States, (iv) a Designated National as defined in the Cuban Assets Control Regulations, 31 C.F.R. Part 515, or (v) a non-U.S. shell
bank or providing banking services indirectly to a non-U.S. shell bank. The Investor agrees to provide law enforcement agencies,
if requested thereby, such records as required by applicable law, provided that the Investor is permitted to do so under applicable
law. If the Investor is a financial institution subject to the Bank Secrecy Act (31 U.S.C. Section 5311 et seq.), as amended by
the USA PATRIOT Act of 2001 and its implementing regulations (collectively, the “BSA/PATRIOT Act”), the Investor
maintains policies and procedures reasonably designed to comply with applicable obligations under the BSA/PATRIOT Act. The Investor
also represents and warrants that, to the extent required by applicable law, it maintains policies and procedures reasonably designed
to ensure compliance with OFAC-administered sanctions programs, including for the screening of its investors against the OFAC sanctions
programs, including the OFAC List. Investor further represents and warrants that, to the extent required by applicable law, the
Investor maintains policies and procedures reasonably designed to ensure that the funds held by the Investor and used to purchase
the Shares were legally derived.

 

m. The
Investor’s acquisition and holding of the Shares will not constitute or result in a non-exempt prohibited transaction under
Section 406 of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), Section 4975 of the
Internal Revenue Code of 1986, as amended (the “Code”), or any other federal, state, local, non-U.S. or other
laws or regulations that are similar to such provisions of ERISA or the Code (collectively, “Similar Laws”).

 

n. If
Investor is, or is acting (directly or indirectly) on behalf of, an employee benefit plan that is subject to Title I of ERISA,
a plan, individual retirement account or other arrangement that is subject to Section 4975 of the Code or an employee benefit plan
that is a governmental plan (as defined in Section 3(32) of ERISA), a church plan (as defined in Section 3(33) of ERISA), a non-U.S.
plan (as described in Section 4(b)(4) of ERISA) or other plan that is not subject to the foregoing but may be subject to provisions
under any Similar Law, or an entity whose underlying assets are considered to include “plan assets” of any such plan,
account or arrangement (each, a “Plan”) subject to the fiduciary or prohibited transaction provisions of ERISA
or Section 4975 of the Code, then the Investor represents and warrants that (i) it has notified VACQ in writing of its status as
a Plan and will provide such additional information as may be requested by the Company in connection therewith, (ii) none of VACQ,
the Company nor any of their respective employees, representatives or affiliates (the “Transaction Parties”)
has acted as the Plan’s fiduciary with respect to its decision to acquire and hold the Shares, and (iii) none of the Transaction
Parties has provided any advice or recommendation, including, without limitation, in a fiduciary capacity, with respect to its
decision to acquire and hold the Shares.

 

    7

    Confidential

    

 

o. No
foreign person (as defined in 31 C.F.R. Part 800.224) in which the national or subnational governments of a single foreign state
have a substantial interest (as defined in 31 C.F.R. Part 800.244) will acquire a substantial interest in VACQ as a result of the
purchase and sale of Shares hereunder such that a declaration to the Committee on Foreign Investment in the United States would
be mandatory under 31 C.F.R. Part 800.401, and no foreign person will have control (as defined in 31 C.F.R. Part 800.208) over
VACQ from and after the Closing as a result of the purchase and sale of Shares hereunder.

 

p. The
Investor acknowledges that no disclosure or offering document has been prepared by Morgan
Stanley & Co. LLC, Deutsche Bank Securities, Inc. or any of their respective affiliates (collectively, the “Placement
Agents”) in connection with the offer and sale of the Shares.

 

q. The
Investor acknowledges that neither Placement Agent, nor any of its respective affiliates nor any control persons, officers, directors,
employees, partners, agents or representatives of any of the foregoing have made any independent investigation with respect to
VACQ, the Company or its subsidiaries or any of their respective businesses, or the Shares or the accuracy, completeness or adequacy
of any information supplied to the Investor by VACQ.

 

r. In
connection with the issue and purchase of the Shares, neither Placement Agent has acted as the Investor’s financial advisor
or fiduciary.

 

s. The
Investor has or has commitments to have and, when required to deliver payment to VACQ pursuant
to Section 2 above, will have, sufficient funds to pay the Subscription Amount and consummate the purchase and sale of the
Shares pursuant to this Subscription Agreement.

 

t. [As of the date hereof
and as of the Closing Date, the Investor represents that no disqualifying event described in Rule 506(d)(1)(i-viii) of the Securities
Act (a “Disqualification Event”) is applicable to the Investor or any of its Rule 506(d) Related Parties (as
defined below), except, if applicable, for a Disqualification Event as to which Rule 506(d)(2)(ii) or (iii) or (d)(3) is applicable.
The Investor hereby agrees that it shall notify VACQ promptly in writing in the event a Disqualification Event becomes applicable
to the Investor or any of its Rule 506(d) Related Parties at or prior to the Closing, except, if applicable, for a Disqualification
Event as to which Rule 506(d)(2)(ii) or (iii) or (d)(3) is applicable. For purposes of this paragraph (t), “Rule 506(d)
Related Party” shall mean a person or entity that is a beneficial owner of the Investor’s securities for purposes
of Rule 506(d) of the Securities Act.]3

 

u. The
Investor agrees that, from the date of this Subscription Agreement, none of the Investor nor any person or entity acting on behalf
of the Investor or pursuant to any understanding with the Investor will engage in any Short Sales with respect to securities of
VACQ prior to the Closing. For the purposes hereof, “Short Sales” shall mean all “short sales” as defined
in Rule 200 promulgated under Regulation SHO under the Exchange Act, and all short positions effected through any direct or indirect
stock pledges (other than pledges in the ordinary course of business as part of prime brokerage arrangements), forward sale contracts,
options, puts, calls, swaps and similar arrangements (including on a total return basis), or sales or other short transactions
through non-U.S. broker dealers or foreign regulated brokers. Notwithstanding the foregoing, nothing herein shall prohibit other
entities under common management with the Investor that have no knowledge of this Subscription Agreement or of Investor’s
participation in this transaction (including the Investor’s controlled affiliates and/or affiliates) from entering into any
Short Sales.

 

v. The
Investor is aware, and acknowledges, that Deutsche Bank Securities Inc. will receive deferred underwriting commissions as disclosed
in the Prospectus (as defined herein) upon the closing of the Transaction.

 

 

 

 

 

 

 

 

	3.	Delete and reserve if investments from Investor’s
ERISA entities constitute less than 25% of Investor’s total investment.

 

    8

    Confidential

    

 

7. Registration
Rights.

 

a. VACQ
agrees that, within 30 calendar days after the consummation of the Transaction (the “Filing Date”), VACQ will
file with the SEC (at VACQ’s sole cost and expense) a registration statement (the “Registration Statement”),
registering the resale of the Shares, which Registration Statement may register the issuance or resale of other shares of the Common
Stock, including, without limitation, shares of the Common Stock issuable upon exercise of the Warrants, and VACQ shall use its
reasonable best efforts to have the Registration Statement declared effective as soon as practicable after the filing thereof,
but no later than the earlier of (i) the 60th calendar day (or 90th calendar day if the SEC notifies VACQ that it will “review”
the Registration Statement) following the Filing Date and (ii) the 10th business day after the date VACQ is notified (orally or
in writing, whichever is earlier) by the SEC that the Registration Statement will not be “reviewed” or will not be
subject to further review (or, in either case of (i) or (ii) above, if such date falls on a Saturday, Sunday or other day that
the SEC is closed for business, the next business day on which the SEC is open for business) (such earlier date, the “Effectiveness
Date”); provided, however, that VACQ’s obligations to include the Shares in the Registration Statement are contingent
upon the Investor furnishing in writing to VACQ such information regarding the Investor, the securities of VACQ held by the Investor
and the intended method of disposition of the Shares as shall be reasonably requested by VACQ to effect the registration of the
Shares, and the Investor shall execute such documents in connection with such registration as VACQ may reasonably request that
are customary of a selling stockholder in similar situations, including providing that VACQ shall be entitled to postpone and suspend
the effectiveness or use of the Registration Statement during any customary blackout or similar period or as permitted hereunder.
Notwithstanding the foregoing, if the SEC prevents VACQ from including any or all of the shares proposed to be registered under
the Registration Statement due to limitations on the use of Rule 415 of the Securities Act for the resale of the Shares by the
applicable stockholders or otherwise, such Registration Statement shall register for resale such number of Shares which is equal
to the maximum number of Shares as is permitted by the SEC. In such event, the number of Shares to be registered for each selling
stockholder named in the Registration Statement shall be reduced pro rata among all such selling stockholders. Upon notification
by the SEC that the Registration Statement has been declared effective by the SEC, within two (2) business days thereafter, VACQ
shall file the final prospectus under Rule 424 of the Securities Act. VACQ will provide a draft of the Registration Statement to
the Investor for review at least two (2) business days in advance of filing the Registration Statement. In no event shall the Investor
be identified as a statutory underwriter in the Registration Statement unless requested by the SEC; provided, that if the SEC requests
that the Investor be identified as a statutory underwriter in the Registration Statement, the Investor will have an opportunity
to withdraw from the Registration Statement. For purposes of clarification, any failure by VACQ to file the Registration Statement
by the Filing Date or to effect such Registration Statement by the Effectiveness Date shall not otherwise relieve VACQ of its obligations
to file or effect the Registration Statement as set forth above in this Section 7.

 

b. In
the case of the registration effected by VACQ pursuant to this Subscription Agreement, VACQ shall, upon reasonable request, inform
the Investor as to the status of such registration. At its expense VACQ shall:

 

(i) except
for such times as VACQ is permitted hereunder to suspend the use of the prospectus forming part of the Registration Statement,
use its commercially reasonable efforts to keep such registration continuously effective with respect to the Investor, and to keep
the Registration Statement (or any subsequent shelf registration statement registers the resale of the Shares by the Investor,
which shall constitute the Registration Statement following its effectiveness) free of any material misstatements or omissions,
until the earlier of the following: (i) the Investor ceases to hold any of the Shares or (ii) the date all of the Shares held by
the Investor may be sold without restriction under Rule 144, including without limitation, any volume and manner of sale restrictions
which may be applicable to affiliates under Rule 144 and without the requirement for VACQ to be in compliance with the current
public information required under Rule 144(c)(1) or Rule 144(i)(2), as applicable, and (iii) two years from the Effectiveness Date.

 

    9

    Confidential

    

 

(ii) advise
the Investor within two (2) business days:

 

(1) when
the Registration Statement or any amendment thereto has been filed with the SEC and when the Registration Statement or any post-effective
amendment thereto has become effective;

 

(2) of
any request by the SEC for amendments or supplements to the Registration Statement or the prospectus included therein or for additional
information with respect to the Investor;

 

(3) of
the issuance by the SEC of any stop order suspending the effectiveness of the Registration Statement or the initiation of any proceedings
for such purpose;

 

(4) of
the receipt by VACQ of any notification with respect to the suspension of the qualification of the Shares included in the Registration
Statement for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and

 

(5) subject
to the provisions in this Subscription Agreement, of the occurrence of any event that requires the making of any changes in the
Registration Statement or prospectus included therein so that, as of such date, the Registration Statement does not contain an
untrue statement of a material fact or does not omit to state a material fact required to be stated therein or necessary to make
the statements therein not misleading, or any prospectus included therein does not include an untrue statement of a material fact
or does not omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading.

 

Notwithstanding anything to the
contrary set forth herein, VACQ shall not, when so advising the Investor of such events, provide the Investor with any material,
nonpublic information regarding VACQ other than to the extent that providing notice to the Investor of the occurrence of the events
listed in (1) through (5) above constitutes material, nonpublic information regarding VACQ;

 

(iii) use
its commercially reasonable efforts to obtain the withdrawal of any order suspending the effectiveness of the Registration Statement
as soon as reasonably practicable;

 

(iv) upon
the occurrence of any event contemplated above, except for a Suspension (as defined below), VACQ shall use its commercially reasonable
efforts to as soon as reasonably practicable prepare a post-effective amendment to the Registration Statement or a supplement to
the related prospectus, or file any other required document so that, as thereafter delivered to purchasers of the Shares included
therein, such prospectus will not include any untrue statement of a material fact or omit to state any material fact necessary
in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;

 

(v) use
its commercially reasonable efforts to cause all of the Shares to be listed on each securities exchange or market, if any, on which
the Common Stock issued by VACQ have been listed;

 

(vi) use
its commercially reasonable efforts to take all other steps necessary to effect the registration of the Shares contemplated hereby
and to enable the Investor to sell the Shares under Rule 144; and

 

    10

    Confidential

    

 

(vii) subject
to receipt from the Investor by VACQ and its transfer agent of customary representations and other documentation reasonably acceptable
to VACQ and the transfer agent in connection therewith, including, if required by the transfer agent, an opinion of VACQ’s
counsel, in a form reasonably acceptable to the transfer agent, to the effect that the removal of such restrictive legends in such
circumstances may be effected under the Securities Act, the Investor may request that VACQ remove any legend from the book entry
position evidencing the Shares following the earliest of such time as the Shares (A) are subject to or have been or are about to
be sold or transferred pursuant to an effective registration statement or (B) have been or are about to be sold pursuant to Rule
144. If restrictive legends are no longer required for the Shares pursuant to the foregoing, VACQ shall, in accordance with the
provisions of this section and reasonably promptly following any request therefor from the Investor accompanied by such customary
and reasonably acceptable representations and other documentation referred to above establishing that restrictive legends are no
longer required, deliver to the transfer agent irrevocable instructions that the transfer agent shall make a new, unlegended entry
for the Shares. VACQ shall be responsible for the fees of its transfer agent associated with such issuance.

 

c. Notwithstanding
anything to the contrary in this Subscription Agreement, VACQ shall be entitled to delay or postpone the effectiveness of the Registration
Statement, and from time to time to require the Investor not to sell under the Registration Statement or to suspend the effectiveness
thereof (such event being referred to as a “Suspension”), if (x) the use of the Registration Statement registration
statement would require the inclusion of financial statements that are unavailable for reasons beyond VACQ’s control or (y)
the negotiation or consummation of a transaction by VACQ or its subsidiaries is pending or an event has occurred, which negotiation,
consummation or event VACQ reasonably believes would require additional disclosure by VACQ in the Registration Statement of information
that VACQ has a bona fide business purpose for keeping confidential and the non-disclosure of which in the Registration Statement
would be expected, in the reasonable determination of VACQ, to cause the Registration Statement to fail to comply with applicable
disclosure requirements (each such circumstance, a “Suspension Event”); provided, however, that VACQ shall not
be entitled to cause a Suspension on more than two occasions or for more than sixty (60) consecutive calendar days, or more than
ninety (90) total calendar days, in each case during any twelve-month period. Upon receipt of any written notice from VACQ of the
happening of a Suspension during the period that the Registration Statement is effective or if as a result of a Suspension Event
the Registration Statement contains any untrue statement of a material fact or omits to state any material fact required to be
stated therein or necessary to make the statements therein not misleading, or any related prospectus includes any untrue statement
of a material fact or omits to state any material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading, the Investor agrees that (i) it will immediately discontinue offers and sales of the
Shares under the Registration Statement until the Investor receives copies of a supplemental or amended prospectus that corrects
the misstatement(s) or omission(s) referred to above and receives notice that any post-effective amendment has become effective
or unless otherwise notified by VACQ that it may resume such offers and sales and (ii) it will maintain the confidentiality of
any information included in such written notice delivered by VACQ unless otherwise required by law or subpoena. If so directed
by VACQ, the Investor will deliver to VACQ or, in the Investor’s sole discretion destroy, all copies of the prospectus covering
the Shares in the Investor’s possession; provided, however, that this obligation to deliver or destroy all copies of the
prospectus covering the Shares shall not apply (A) to the extent the Investor is required to retain a copy of such prospectus (x)
in order to comply with applicable legal, regulatory, self-regulatory or professional requirements or (y) in accordance with a
bona fide pre-existing document retention policy or (B) to copies stored electronically on archival servers as a result of automatic
data back-up.

 

d. The
Investor may deliver written notice (an “Opt-Out Notice”) to VACQ requesting that the Investor not receive notices
from VACQ otherwise required by this Section 7; provided, however, that the Investor may later revoke any such Opt-Out Notice
in writing. Following receipt of an Opt-Out Notice from the Investor (unless subsequently revoked), (i) VACQ shall not deliver
any such notices to the Investor and the Investor shall no longer be entitled to the rights associated with any such notice and
(ii) each time prior to the Investor’s intended use of the Registration Statement, the Investor will notify VACQ in writing
at least two (2) business days in advance of such intended use, and if a notice of a Suspension or Suspension Event that still
applies was previously delivered (or would have been delivered but for the provisions of this Section 7(d)), VACQ will so
notify the Investor, within one (1) business day of the Investor’s notification to VACQ, by delivering to the Investor a
copy of such previous notice of the Suspension or Suspension Event, and thereafter will provide the Investor with the related notice
of the conclusion the Suspension or that such Suspension Event no longer applies immediately upon its availability.

 

    11

    Confidential

    

 

e. VACQ
shall, notwithstanding any termination of this Subscription Agreement, indemnify, defend and hold harmless the Investor (to the
extent a seller under the Registration Statement), its directors, officers, agents and employees and each person who controls the
Investor (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) to the fullest extent permitted
by applicable law, from and against any and all out-of-pocket losses, claims, damages, liabilities, costs (including reasonable
attorneys’ fees) and expenses (collectively, “Losses”), as incurred, that arise out of or are based upon
(i) any untrue or alleged untrue statement of a material fact contained in the Registration Statement or in any amendment or supplement
thereto, required to be stated therein or necessary to make the statements therein not misleading or (ii) any untrue or alleged
untrue statement of a material fact included in any prospectus included in the Registration Statement or any form of prospectus
or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged
omission to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading, except to the extent, but only to the extent, that such untrue statements, alleged untrue statements,
omissions or alleged omissions are based upon information regarding the Investor furnished in writing to VACQ by the Investor expressly
for use therein or the Investor has omitted a material fact from such information or otherwise violated the Securities Act, Exchange
Act or any state securities law or any rule or regulation thereunder; provided, however, that the indemnification contained in
this Section 7 shall not apply to amounts paid in settlement of any Losses if such settlement is effected without the consent
of VACQ, which shall not be unreasonably withheld, conditioned or delayed, nor shall VACQ be liable for any Losses to the extent
they arise out of or are based upon a violation which occurs (A) in reliance upon and in conformity with written information furnished
by the Investor, (B) in connection with any failure of such person to deliver or cause to be delivered a prospectus made available
by VACQ in a timely manner or (C) in connection with any offers or sales effected by or on behalf of the Investor in violation
of Section 7(c) hereof. VACQ shall notify the Investor reasonably promptly of the institution, threat or assertion of any
proceeding arising from or in connection with the transactions contemplated by this Section 7 of which VACQ receives notice
in writing. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of an indemnified
party and shall survive the transfer of the Shares by the Investor.

 

f. The
Investor shall, severally and not jointly, indemnify and hold harmless VACQ, its directors, officers, agents and employees, and
each person who controls VACQ (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), to the
fullest extent permitted by applicable law, from and against all Losses, as incurred, (i) arising out of or based upon any untrue
or alleged untrue statement of a material fact contained in any Registration Statement or in any amendment or supplement thereto
or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary
to make the statements therein not misleading or (ii) arising out of or based upon any untrue or alleged untrue statement of a
material fact included in any prospectus included in the Registration Statement or any form of prospectus or in any amendment or
supplement thereto or in any preliminary prospectus or arising out of or relating to any omission or alleged omission of a material
fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading,
with respect to (i) and/or (ii), to the extent, but only to the extent, that such untrue or alleged untrue statements or omissions
or alleged omissions are based upon information regarding the Investor furnished in writing to VACQ by the Investor expressly for
use therein; provided, however, that the indemnification contained in this Section 7(f) shall not apply to amounts paid
in settlement of any Losses if such settlement is effected without the consent of the Investor. In no event shall the liability
of the Investor be greater in amount than the dollar amount of the net proceeds received by the Investor upon the sale of the Shares
giving rise to such indemnification obligation. The Investor shall notify VACQ promptly of the institution, threat or assertion
of any proceeding arising from or in connection with the transactions contemplated by this Section 7(f) of which the Investor
is aware. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of an indemnified
party and shall survive the transfer of the Shares by the Investor.

 

g. If
the indemnification provided under this Section 7 from the indemnifying party is unavailable or insufficient to hold harmless
an indemnified party in respect of any Losses, then the indemnifying party, in lieu of indemnifying the indemnified party, shall
contribute to the amount paid or payable by the indemnified party as a result of such Losses in such proportion as is appropriate
to reflect the relative fault of the indemnifying party and the indemnified party, as well as any other relevant equitable considerations.
The relative fault of the indemnifying party and indemnified party shall be determined by reference to, among other things, whether
any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission to
state a material fact, was made by, or relates to information supplied by, such indemnifying party or indemnified party, and the
indemnifying party’s and indemnified party’s relative intent, knowledge, access to information and opportunity to correct
or prevent such action. The amount paid or payable by a party as a result of the Losses shall be deemed to include, subject to
the limitations set forth above, any legal or other fees, charges or expenses reasonably incurred by such party in connection with
any investigation or proceeding. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities
Act) shall be entitled to contribution pursuant to this Section 7(g) from any person who was not guilty of such fraudulent
misrepresentation. In no event shall the liability of the Investor be greater in amount than the dollar amount of the net proceeds
received by the Investor upon the sale of the Shares purchased pursuant to this Subscription Agreement giving rise to such contribution
obligation.

 

    12

    Confidential

    

 

8. Termination.
This Subscription Agreement shall terminate and be void and of no further force and effect, and all rights and obligations of
the parties hereunder shall terminate without any further liability on the part of any party in respect thereof, upon the earlier
to occur of (a) such date and time as the Merger Agreement is terminated in accordance with its terms without being consummated,
(b) upon the mutual written agreement of each of the parties hereto and the Company to terminate this Subscription Agreement,
(c) 30 days after the Outside Date (as defined in the Merger Agreement), if the Closing has not occurred by such date, or (d)
by written notice of the Investor to VACQ in the event the Merger Agreement is amended, supplemented or otherwise modified after
the date hereof in a manner that materially adversely affects the Investor (the termination events described in clauses (a)–(d)
above, collectively, the “Termination Events”); provided that nothing herein will relieve any party from liability
for any willful breach hereof prior to the time of termination, and each party will be entitled to any remedies at law or in equity
to recover losses, liabilities or damages arising from any such willful breach. VACQ shall notify the Investor in writing of the
termination of the Merger Agreement promptly after the termination of such agreement. Upon the occurrence of any Termination Event,
this Subscription Agreement shall be void and of no further effect and any monies paid by the Investor to VACQ in connection herewith
shall promptly (and in any event within one business day) following a Termination Event be returned to the Investor.

 

9. Trust
Account Waiver. The Investor acknowledges that VACQ is a blank check company with the powers and privileges to effect a merger,
asset acquisition, reorganization or similar business combination involving VACQ and one or more businesses or assets. The Investor
further acknowledges that, as described in VACQ’s prospectus relating to its initial public offering dated September 24,
2020 (the “Prospectus”) available at www.sec.gov, substantially all of VACQ’s assets consist of the cash proceeds
of VACQ’s initial public offering and private placement of its securities, and substantially all of those proceeds have
been deposited in a trust account (the “Trust Account”) for the benefit of VACQ, its public shareholders and the underwriters
of VACQ’s initial public offering. Except with respect to interest earned on the funds held in the Trust Account that may
be released to VACQ to pay its tax obligations, if any, the cash in the Trust Account may be disbursed only for the purposes set
forth in the Prospectus. For and in consideration of VACQ entering into this Subscription Agreement, the receipt and sufficiency
of which are hereby acknowledged, the Investor hereby irrevocably waives any and all right, title and interest, or any claim of
any kind it has or may have in the future, in or to any monies held in the Trust Account, and agrees not to seek recourse against
the Trust Account, regardless of whether such claim arises as a result of, in connection with or relating in any way to, this
Subscription Agreement or any other matter, and regardless of whether such claim arises based on contract, tort, equity or any
other theory of liability (the “Released Claims”); provided, that the Released Claims shall not include any
claims that the Investor may have solely in the Investor’s capacity as a record or beneficial holder of any Class A Ordinary
Shares.

 

10. Miscellaneous.

 

a. Neither
this Subscription Agreement nor any rights that may accrue to the parties hereunder (other than the Shares acquired hereunder,
if any) may be transferred or assigned without the prior written consent of each of the other parties hereto; provided that
this Subscription Agreement and any of the Investor’s rights and obligations hereunder may be assigned to one or more of
its affiliates (including any investment fund or account managed or advised by the same investment manager as the Investor or by
an affiliate of such investment manager) without the prior consent of VACQ; provided further that (x) prior to such assignment
any such assignee shall agree in writing to be bound by the terms hereof and (y) no such assignment shall relieve the Investor
of its obligations hereunder if any such assignee fails to fully perform such obligations.

 

b. VACQ
may request from the Investor such additional information as VACQ may reasonably deem necessary to register the resale of the Shares
and evaluate the eligibility of the Investor to acquire the Shares, and the Investor shall provide such information as may reasonably
be requested to the extent readily available and to the extent consistent with its internal policies and procedures; provided that
VACQ expressly agrees to keep any such information provided by the Investor confidential except (i) as required by the applicable
securities laws or pursuant to proceedings of regulatory authorities or (ii) to the extent such disclosure is required by law,
at the request of the staff of the SEC or other regulatory agency or under the regulations of any national securities exchange
on which VACQ’s securities are listed for trading. The Investor acknowledges that VACQ may file a copy of this Subscription
Agreement with the SEC as an exhibit to a periodic report or a registration statement of VACQ.

 

    13

    Confidential

    

 

c. The
Investor acknowledges that VACQ, the Company, the Placement Agents and others will rely on the acknowledgments, understandings,
agreements, representations and warranties contained in this Subscription Agreement. Prior to the Closing, each party hereto agrees
to promptly notify the other party hereto if any of the acknowledgments, understandings, agreements, representations and warranties
set forth herein with respect to it are no longer accurate.

 

d. VACQ,
the Company and the Placement Agents are each entitled to rely upon this Subscription Agreement and each is irrevocably authorized
to produce this Subscription Agreement or a copy hereof to any interested party in any administrative or legal proceeding or official
inquiry with respect to the matters covered hereby to the extent required by law or regulatory bodies; provided, however,
that the foregoing clause of this Section 10(d) shall not give the Company or the Placement Agents any rights other than
those expressly set forth herein and, without limiting the generality of the foregoing and for the avoidance of doubt, in no event
shall the Company be entitled to rely on any of the representations and warranties of VACQ set forth in this Subscription Agreement.

 

e. All
of the agreements, representations and warranties made by each party hereto in this Subscription Agreement shall survive the Closing.

 

f. This
Subscription Agreement may not be modified, waived or terminated (other than pursuant to the terms of Section 8 above) except
by an instrument in writing, signed by each of the parties hereto, provided, however, that no modification or waiver by
VACQ of the provisions of this Subscription Agreement shall be effective without the prior written consent of the Company (other
than modifications or waivers that are solely ministerial in nature or otherwise immaterial and do not affect any economic or any
other material term of this Subscription Agreement). No failure or delay of either party in exercising any right or remedy hereunder
shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any abandonment or discontinuance
of steps to enforce such right or power, or any course of conduct, preclude any other or further exercise thereof or the exercise
of any other right or power. The rights and remedies of the parties hereunder are cumulative and are not exclusive of any rights
or remedies that they would otherwise have hereunder.

 

g. This
Subscription Agreement (including the schedule hereto) constitutes the entire agreement, and supersedes all other prior agreements,
understandings, representations and warranties, both written and oral, among the parties, with respect to the subject matter hereof.
Except as set forth in Section 7, Section 10(c), Section 10(d), Section 10(f), this Section 10(g)
and Section 11 with respect to the persons specifically referenced therein, this Subscription Agreement shall not confer
any rights or remedies upon any person other than the parties hereto, and their respective successor and assigns, and the parties
hereto acknowledge that such persons so referenced are third party beneficiaries of this Subscription Agreement for the purposes
of, and to the extent of, the rights granted to them, if any, pursuant to the applicable provisions.

 

h. Except
as otherwise provided herein, this Subscription Agreement shall be binding upon, and inure to the benefit of the parties hereto
and their heirs, executors, administrators, successors, legal representatives, and permitted assigns, and the agreements, representations,
warranties, covenants and acknowledgments contained herein shall be deemed to be made by, and be binding upon, such heirs, executors,
administrators, successors, legal representatives and permitted assigns.

 

i. If
any provision of this Subscription Agreement shall be adjudicated by a court of competent jurisdiction to be invalid, illegal or
unenforceable, the validity, legality or enforceability of the remaining provisions of this Subscription Agreement shall not in
any way be affected or impaired thereby and shall continue in full force and effect.

 

j. This
Subscription Agreement may be executed in one or more counterparts (including by facsimile or electronic mail or in .pdf or by
www.docusign.com or similar service) and by different parties in separate counterparts, with the same effect as if all parties
hereto had signed the same document. All counterparts so executed and delivered shall be construed together and shall constitute
one and the same agreement.

 

    14

    Confidential

    

 

k. The
parties hereto acknowledge and agree that irreparable damage would occur in the event that any of the provisions of this Subscription
Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that
the parties shall be entitled to seek an injunction or injunctions to prevent breaches or threatened breaches of this Subscription
Agreement, without posting a bond or undertaking and without proof of damages, to enforce specifically the terms and provisions
of this Subscription Agreement, this being in addition to any other remedy to which such party is entitled at law, in equity, in
contract, in tort or otherwise. The right to specific enforcement shall include the right of each party hereto to cause the other
party hereto to cause the transactions contemplated hereby to be consummated on the terms and subject to the conditions and limitations
set forth in this Subscription Agreement.

 

l. This
Subscription Agreement shall be governed by and construed in accordance with the laws of the State of Delaware (regardless of the
laws that might otherwise govern under applicable principles of conflicts of laws thereof) as to all matters (including any action,
suit, litigation, arbitration, mediation, claim, charge, complaint, inquiry, proceeding, hearing, audit, investigation or reviews
by or before any governmental entity related hereto), including matters of validity, construction, effect, performance and remedies.

 

m. Each
party hereto and any person asserting rights as a third party beneficiary may do so only if he, she or it irrevocably agrees that
any action, suit or proceeding between or among the parties hereto, whether arising in contract, tort or otherwise, arising in
connection with any disagreement, dispute, controversy or claim arising out of or relating to this Subscription Agreement or any
related document or any of the transactions contemplated hereby or thereby (“Legal Dispute”) shall be brought
only to the exclusive jurisdiction of the courts of the State of Delaware or the federal courts located in the State of Delaware,
and each party hereto hereby consents to the jurisdiction of such courts (and of the appropriate appellate courts therefrom) in
any such suit, action or proceeding and irrevocably waives, to the fullest extent permitted by law, any objection that it may now
or hereafter have to the laying of the venue of any such suit, action or proceeding in any such court or that any such suit, action
or proceeding that is brought in any such court has been brought in an inconvenient forum. During the period a Legal Dispute that
is filed in accordance with this Section 10(m) is pending before a court, all actions, suits or proceedings with respect
to such Legal Dispute or any other Legal Dispute, including any counterclaim, cross-claim or interpleader, shall be subject to
the exclusive jurisdiction of such court. Each party hereto and any person asserting rights as a third party beneficiary may do
so only if he, she or it hereby waives, and shall not assert as a defense in any Legal Dispute, that (i) such party is not
personally subject to the jurisdiction of the above named courts for any reason, (ii) such action, suit or proceeding may
not be brought or is not maintainable in such court, (iii) such party’s property is exempt or immune from execution,
(iv) such action, suit or proceeding is brought in an inconvenient forum, or (v) the venue of such action, suit or proceeding
is improper. A final judgment in any action, suit or proceeding described in this Section 10(m) following the expiration
of any period permitted for appeal and subject to any stay during appeal shall be conclusive and may be enforced in other jurisdictions
by suit on the judgment or in any other manner provided by applicable Laws. EACH OF THE PARTIES HERETO AND ANY PERSON ASSERTING
RIGHTS AS A THIRD PARTY BENEFICIARY MAY DO SO ONLY IF HE, SHE OR IT IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT TO TRIAL BY
JURY ON ANY CLAIMS OR COUNTERCLAIMS ASSERTED IN ANY LEGAL DISPUTE RELATING TO THIS SUBSCRIPTION AGREEMENT OR THE TRANSACTIONS CONTEMPLATED
HEREBY AND FOR ANY COUNTERCLAIM RELATING THERETO. IF THE SUBJECT MATTER OF ANY SUCH LEGAL DISPUTE IS ONE IN WHICH THE WAIVER OF
JURY TRIAL IS PROHIBITED, NO PARTY HERETO NOR ANY PERSON ASSERTING RIGHTS AS A THIRD PARTY BENEFICIARY SHALL ASSERT IN SUCH LEGAL
DISPUTE A NONCOMPULSORY COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS SUBSCRIPTION AGREEMENT OR THE TRANSACTIONS CONTEMPLATED
HEREBY. FURTHERMORE, NO PARTY HERETO NOR ANY PERSON ASSERTING RIGHTS AS A THIRD PARTY BENEFICIARY SHALL SEEK TO CONSOLIDATE ANY
SUCH LEGAL DISPUTE WITH A SEPARATE ACTION OR OTHER LEGAL PROCEEDING IN WHICH A JURY TRIAL CANNOT BE WAIVED.

 

    15

    Confidential

    

 

n. The
Investor hereby consents to the publication and disclosure in any Form 8-K filed by VACQ with the SEC in connection with the execution
and delivery of the Merger Agreement or the transactions contemplated thereby and the Registration Statement (as defined in the
Merger Agreement) (and, to the extent otherwise required by the federal securities laws, exchange rules, the SEC or any other securities
authorities or any rules and regulations promulgated thereby, any other documents or communications provided by VACQ or the Company
to any governmental entity or to any securityholders of VACQ or the Company) of the Investor’s identity and beneficial ownership
of the subscribed Shares and the nature of the Investor’s commitments, arrangements and understandings under and relating
to this Subscription Agreement and, if deemed reasonably necessary by VACQ or the Company, a form of this Subscription Agreement,
all solely to the extent required by applicable law or any regulation or stock exchange listing requirement, in which case, VACQ
shall provide the Investor with prior written notice (including by e-mail) of such permitted disclosure. The Investor will promptly
provide any information reasonably requested by VACQ or the Company for any regulatory application or filing made or approval sought
in connection with the Transaction (including filings with the SEC).

 

o. VACQ
shall, by 9:30 a.m., New York City time, on the first (1st) business day immediately following the date of this Subscription Agreement,
issue one or more press releases or file with the SEC a Current Report on Form 8-K (collectively, the “Disclosure Document”)
disclosing, to the extent not previously publicly disclosed, all material terms of the transactions contemplated hereby (and of
the other subscription agreements related to the private placement of the Shares entered into prior to the release or filing of
such Disclosure Document), the Transaction and any other material, non-public information that VACQ or the Company has provided
to the Investor at any time prior to the filing of the Disclosure Document. As of immediately following the filing of the Disclosure
Document with the SEC, to the knowledge of VACQ, the Investor shall not be in possession of any material, non-public information
received from VACQ, the Company, any of their respective subsidiaries or any of their respective officers, directors, employees,
affiliates or agents or the Placement Agents that is not disclosed in the Disclosure Document or in prior filings with the SEC.
In addition, effective upon the filing of the Disclosure Document, VACQ acknowledges and agrees that any and all confidentiality
or similar obligations under any agreement, whether written or oral, between VACQ, on the one hand, and the Investor or any of
its affiliates, on the other hand, relating to the transactions contemplated by this Subscription Agreement shall terminate and
be of no further force or effect.

 

p. If
any change in the number, type or classes of authorized shares of VACQ (including the Shares) shall occur between the date hereof
and immediately prior to the Closing by reason of reclassification, recapitalization, stock split (including reverse stock split)
or combination, exchange or readjustment of shares, or any stock dividend, the number of Shares issued to the Investor shall be
appropriately adjusted to reflect such change.

 

11. Non-Reliance.
The Investor acknowledges that it is not relying upon, and has not relied upon, any statement, representation or warranty made
by any person, firm or corporation (including, without limitation, the Company, the Placement
Agents, any of their respective affiliates or any control persons, officers, directors, employees, partners, agents or
representatives of any of the foregoing), other than the statements, representations and warranties of VACQ expressly contained
in this Subscription Agreement, in making its investment or decision to invest in VACQ.

 

[SIGNATURE PAGES FOLLOW]

 

    16

    Confidential

    

 

IN WITNESS WHEREOF,
the Investor has executed or caused this Subscription Agreement to be executed by its duly authorized representative as of the
date set forth below.

 

	Name of Investor:	State/Country of Formation or Domicile:
	 	 
	By:  _____________________________________	 
	Name:  ___________________________________	 
	Title:  ___________________________________	 
	 	 
	Name in which Shares are to be registered (if different):	Date: ________, 2021
	 	 
	Investor’s EIN:	 
	 	 
	Business Address-Street:	Mailing Address-Street (if different):
	 	 
	City, State, Zip:	City, State, Zip:
	 	 
	Attn:  ____________________________________	Attn:  ____________________________________
	Telephone No.:	Telephone No.:
	Facsimile No.:	Facsimile No.:
	Number of Shares subscribed for:	 
	Aggregate Subscription Amount: $	Price Per Share: $10.00

 

You must pay the Subscription
Amount by wire transfer of United States dollars in immediately available funds to the account specified by VACQ in the Closing
Notice. To the extent the offering is oversubscribed, the number of Shares received may be less than the number of Shares subscribed
for.

 

Signature Page
to Subscription Agreement

 

    17

    Confidential

    

 

IN WITNESS WHEREOF,
Vector Acquisition Corporation has accepted this Subscription Agreement as of the date set forth below.

 

	 	VECTOR ACQUISITION CORPORATION
	 	 
	 	By: 	             
	 	Name:	 
	 	Title:	 

 

Date: , 2021

 

Signature Page
to Subscription Agreement

 

     

     

    

  

SCHEDULE A

  

ELIGIBILITY
REPRESENTATIONS OF THE INVESTOR

 

	A.	QUALIFIED INSTITUTIONAL BUYER STATUS

 

	 	(Please check the applicable subparagraphs):

 

☐  We
are a “qualified institutional buyer” (as defined in Rule 144A under the Securities Act (a “QIB”)).

 

**OR**

 

	B.	INSTITUTIONAL ACCREDITED INVESTOR STATUS

 

	 	(Please check the applicable subparagraphs):

 

	 	1.	☐  We are an “accredited investor” (within the meaning of Rule 501(a) under the Securities Act or an entity in which all of the equity holders are accredited investors within the meaning of Rule 501(a) under the Securities Act), and have marked and initialed the appropriate box below indicating the provision under which we qualify as an “accredited investor.”

 

	 	2.    ☐  We are not a natural person.

 

Rule
501(a), in relevant part, states that an “accredited investor” shall mean any person who comes within any of the below
listed categories, or who VACQ reasonably believes comes within any of the below listed categories, at the time of the sale of
the securities to that person. The Investor has indicated, by marking and initialing the appropriate box below, the provision(s)
below which apply to the Investor and under which the Investor accordingly qualifies as an “accredited investor.”

 

☐  Any
bank, registered broker or dealer, insurance company, registered investment company, business development company, or small business
investment company, as described in Rule 501(a)(1) or (2);

 

☐  Any
plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political
subdivisions for the benefit of its employees, if such plan has total assets in excess of $5,000,000;

 

☐  Any
employee benefit plan, within the meaning of the Employee Retirement Income Security Act of 1974, if a bank, insurance company,
or registered investment adviser makes the investment decisions, or if the plan has total assets in excess of $5,000,000;

 

☐  Any
organization described in Section 501(c)(3) of the Internal Revenue Code, corporation, Massachusetts or similar business trust,
partnership, or limited liability company, not formed for the specific purpose of acquiring the securities offered, with total
assets in excess of $5,000,000;

 

☐  Any
trust with assets in excess of $5,000,000, not formed to acquire the securities offered, whose purchase is directed by a sophisticated
person as described in Rule 506(b)(2)(ii); or

 

☐  Any
entity in which all of the equity owners are accredited investors.

 

     

     

    

 

This
page should be completed by the Investor

and
constitutes a part of the Subscription Agreement.

 

SCHEDULE B

 

 

Morgan Stanley & Co.
LLC

1585 Broadway

New York, New York 10036

 

Deutsche Bank Securities,
Inc.

60 Wall Street

New York, New York 10005

 

Re:Purchase of Common
Stock, par value $0.0001 per share (the “Securities”), issued by Vector Acquisition Corporation (the “Company”)

 

Ladies and Gentlemen:

 

In
connection with the offer and sale of the Securities to be issued by the Company, we represent, warrant, agree and acknowledge
as follows:

 

1. No
disclosure or offering document has been prepared in connection with the offer and sale of the Securities by Morgan Stanley &
Co. LLC or Deutsche Bank Securities, Inc. (collectively, the “Placement Agents”) or any of their affiliates.

 

2. (a)
We have conducted our own investigation of the Company, the proposed transaction (the “Transaction”) between
the Company and Rocket Lab USA, Inc. (“Rocket Lab”), the business of Rocket Lab and its subsidiaries and the
Securities and we have not relied on any statements or other information provided by the Placement Agents concerning the Company,
the Transaction, the business of Rocket Lab and its subsidiaries or the Securities or the offer and sale of the Securities, (b)
we have had access to, and an adequate opportunity to review, financial and other information as we deem necessary to make our
decision to purchase the Securities, (c) we have been offered the opportunity to ask questions of the Company and received answers
thereto, as we deemed necessary in connection with our decision to purchase the Securities; and (d) we have made our own assessment
and have satisfied ourselves concerning the relevant tax and other economic considerations relevant to our investment in the Securities.

 

3. The
Placement Agents and their respective directors, officers, employees, representatives and controlling persons have made no independent
investigation with respect to the Company, the Transaction, the business of Rocket Lab and its subsidiaries or the Securities or
the accuracy, completeness or adequacy of any information supplied to us by the Company.

 

4. In
connection with the issue and purchase of the Securities, neither of the Placement Agents has acted as our financial advisor or
fiduciary.

 

5. We
are (x) a qualified institutional buyer (as defined in Rule 144A of the Securities Act of 1933 as amended (the “Securities
Act”)), or (y) an accredited investor described in Rule 501(a)(1), (2), (3), (7) or (8) of
the Securities Act. Accordingly, we understand that the offering meets the exemptions from filing under FINRA Rule 5123(b)(1)(C)
or (J). 

 

6. We
(i) are an institutional account as defined in FINRA Rule 4512(c), (ii) are a sophisticated investor, experienced in investing
in private equity transactions and capable of evaluating investment risks independently, both in general and with regard to all
transactions and investment strategies involving a security or securities and (iii) have exercised independent judgment in evaluating
our participation in the purchase of the Securities. Accordingly, we understand that the offering meets (i) the exemptions from
filing under FINRA Rule 5123(b)(1)(A) and (ii) the institutional customer exemption under FINRA Rule 2111(b).

 

7. We
are aware that the sale to us is being made in reliance on a private placement exemption from registration under the Securities
Act and are acquiring the Securities for our own account or for an account over which we exercise sole discretion for another qualified
institutional buyer or accredited investor.

 

     

     

    

 

8. We
are able to fend for ourselves in the transactions contemplated herein; have such knowledge and experience in financial and business
matters as to be capable of evaluating the merits and risks of our prospective investment in the Securities; and have the ability
to bear the economic risks of our prospective investment and can afford the complete loss of such investment.

 

9. The
Securities have not been registered under the Securities Act or any other applicable securities laws, are being offered for resale
in transactions not requiring registration under the Securities Act, and unless so registered, may not be offered, sold or otherwise
transferred except in compliance with the registration requirements of the Securities Act or any other applicable securities laws,
pursuant to any exemption therefrom or in a transaction not subject thereto.

  

Very truly yours,

 

[NAME OF INVESTOR]

 

	By:	 	 
	Name: 	 	 
	Title:	 	 

 

Date:Exhibit 10.2

 

March 1, 2021

 

Vector Acquisition Corporation

One Market Street

Steuart Tower, 23rd Floor

San Francisco, CA 94105

 

Reference is made to
that certain Agreement and Plan of Merger, dated as of the date hereof (the “Merger Agreement”), by and among
Vector Acquisition Corporation, a Cayman Islands exempted company (which will domesticate as a Delaware corporation prior to the
Closing) (“Parent”), Rocket Lab USA, Inc., a Delaware corporation (the “Company”), and Prestige
USA Merger Sub, Inc., a Delaware corporation and a direct, wholly-owned Subsidiary of the Company (“Merger Sub”).

 

This letter
agreement (this “Letter Agreement”) is being entered into and delivered by Parent and Vector Acquisition
Partners, L.P., a Cayman Islands exempted limited partnership (“Sponsor”), in connection with the
transactions contemplated by the Merger Agreement. Capitalized terms used but not otherwise defined herein shall have the
meanings ascribed to such terms in the Merger Agreement.

 

In consideration of
the foregoing and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Parent
and Sponsor hereby agree as follows:

 

		1.	Sponsor hereby agrees to vote at any meeting of the shareholders of Parent, and in any action by
written resolution of the shareholders of Parent, all of such Parent Class B Ordinary Shares (together with any other equity securities
of Parent that Sponsor holds of record or beneficially, as of the date of this Agreement, or acquires record or beneficial ownership
after the date hereof) in favor of the Domestication. Sponsor hereby agrees to vote at any meeting of the stockholders of Parent,
and in any action by written resolution of the stockholders of Parent, all of such Delaware Parent Common Stock received by Sponsor
in connection with the Domestication in favor of each of the other Parent Stockholder Matters.

 

		2.	Subject to the satisfaction or waiver of each of the conditions to Closing set forth in the Merger
Agreement and subject to the terms of the Merger Agreement, effective immediately prior to and conditioned upon the Closing, Sponsor
hereby waives any and all rights it has or will have to adjustment or other anti-dilution protection with respect to the rate that
the Parent Class B Ordinary Shares held by Sponsor convert into Parent Class A Ordinary Shares, including under Articles 14 through
18 of Parent’s Second Amended and Restated Articles of Association, dated September 24, 2020, to receive more than one Parent
Class A Ordinary Share upon automatic conversion of Parent Class B Ordinary Shares in connection with the Transactions, it being
understood and agreed that, subject to the terms of the Merger Agreement, all Parent Class B Ordinary Shares shall convert into
Parent Class A Ordinary Shares on a one-for-one basis and that this provision shall apply, mutatis mutandis, to any shares
of Delaware Parent Common Stock received in the Domestication (the “Parent Ordinary Shares”).

 

     

     

    

 

		3.	Except for this Letter Agreement or as described in the Merger Agreement or Parent’s prospectus
dated September 24, 2020 and filed on September 28, 2020, from and after the date of this Agreement and until the Termination Date
(as defined below), prior to the receipt of the Requisite Parent Stockholder Approval, Sponsor agrees not to (i) enter into any
voting agreement, voting trust or any similar agreement, arrangement or understanding, with respect to any Parent Ordinary Shares
or other equity securities of Parent owned by Sponsor (including any Delaware Parent Common Stock), (ii) grant any proxy, consent
or power of attorney with respect to any Parent Ordinary Shares or other equity securities of Parent owned by Sponsor (including
any Delaware Parent Common Stock), (iii) enter into any agreement, arrangement or understanding that is otherwise inconsistent
with, or would interfere with, or prohibit or prevent it from satisfying, its obligations pursuant to this Letter Agreement or
(iv) sell, assign, transfer (including by operation of law), place a lien on, pledge, dispose of or otherwise encumber any of its
Parent Ordinary Shares or other equity securities of Parent owned by Sponsor (including any Delaware Parent Common Stock) or otherwise
agree to do any of the foregoing (each, a “Transfer”); provided, however, that the foregoing shall not apply
to any Transfer (A) to Parent’s officers or directors, any affiliates or family member of any of Parent’s officers
or directors, any members or partners of the Sponsor or their affiliates, any affiliates of the Sponsor, or any employees of such
affiliates; (B) in the case of an individual, by gift to a member of one of the individual’s immediate family or to a trust,
the beneficiary of which is a member of the individual’s immediate family, an affiliate of such person or to a charitable
organization; (C) in the case of an individual, by virtue of laws of descent and distribution upon death of the individual; (D)
in the case of an individual, pursuant to a qualified domestic relations order; (E) by private sales or transfers made in connection
with the transactions contemplated by the Merger Agreement; and (F) by virtue of the Sponsor’s organizational documents upon
liquidation or dissolution of Sponsor; provided, that any transferee of any Transfer of the type set forth in clauses (A) through
(F) must enter into a written agreement in form and substance reasonably satisfactory to the Company agreeing to be bound by this
Agreement prior to the occurrence of such Transfer. In furtherance of the foregoing, Parent hereby agrees to (i) place a revocable
stop order on all Parent Ordinary Shares or other equity securities of Parent (including any Delaware Parent Common Stock) subject
to this Section 4, including those which may be covered by a registration statement, and (ii) notify Parent’s
transfer agent in writing of such stop order and the restrictions on such Parent Ordinary Shares or other equity securities of
Parent (including any Delaware Parent Common Stock) subject to this Section 4, under and direct Parent’s transfer
agent not to process any attempts by Sponsor to Transfer any Parent Ordinary Shares or other equity securities of Parent (including
any Delaware Parent Common Stock) subject to this Section 4, except in compliance with this Section 4. For the avoidance
of doubt, the obligations of Parent under this Section 4 shall be deemed to be satisfied by the existence of any similar
stop order and restrictions currently existing on the Parent Class A Ordinary Shares or other equity securities of Parent (including
any Delaware Parent Common Stock) subject to this Section 4.

 

    2

     

    

 

		4.	Sponsor hereby represents and warrants to Parent as follows:

 

(a) As
of the date hereof, it holds 7,950,000 of the issued and outstanding Parent Class B Ordinary Shares.

 

(b) Sponsor
has the full power and authority to make, enter into and carry out the terms of this Letter Agreement. This Letter Agreement has
been duly and validly executed and delivered by Sponsor and constitutes a valid and binding agreement of Sponsor enforceable against
it in accordance with its terms, except insofar as enforceability may be limited by the Remedies Exception.

 

(c) The
execution and delivery of this Letter Agreement by Sponsor does not, and the performance by Sponsor of the obligations under this
Letter Agreement and the compliance by Sponsor with any provisions hereof do not and will not: (i) conflict with or violate any
Law applicable to Sponsor, (ii) contravene or conflict with, or result in any violation or breach of, any provision of any charter,
articles of association, operating agreement or similar formation or governing documents and instruments of Sponsor, or (iii) result
in any material breach of or constitute a material default (or an event that with notice or lapse of time or both would become
a material default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, or result in
the creation of a Lien on any of the Parent Ordinary Shares owned by Sponsor pursuant to any Contract to which Sponsor is a party
or by which Sponsor is bound, except, in the case of clause (i), (ii) or (iii), as would not reasonably be expected, either individually
or in the aggregate, to materially impair the ability of Sponsor to perform its obligations hereunder or to consummate the transactions
contemplated hereby.

 

(d) No
consent, approval, order or authorization of, or registration, declaration or filing with, any Governmental Entity or any other
Person is required by or with respect to Sponsor in connection with the execution and delivery of this Letter Agreement or the
consummation by Sponsor of the transactions contemplated hereby, except as would not reasonably be expected, either individually
or in the aggregate, to materially impair the ability of Sponsor to perform its obligations hereunder or to consummate the transactions
contemplated hereby.

 

(e) As
of the date hereof, there is no action pending against, or, to the knowledge of Sponsor, threatened against Sponsor that would
reasonably be expected to materially impair the ability of Sponsor to perform its obligations hereunder or to consummate the transactions
contemplated hereby.

 

(f) Except
for this Letter Agreement or as described in Parent’s prospectus dated September 24, 2020 and filed on September 28, 2020,
Sponsor has not: (i) entered into any voting agreement, voting trust or any similar agreement, arrangement or understanding, with
respect to any Parent Ordinary Shares or other equity securities of Parent owned by Sponsor, (ii) granted any proxy, consent or
power of attorney with respect to any Parent Ordinary Shares or other equity securities of Parent owned by Sponsor or (iii) entered
into any agreement, arrangement or understanding that is otherwise inconsistent with, or would interfere with, or prohibit or prevent
it from satisfying, its obligations pursuant to this Letter Agreement.

 

    3

     

    

 

(g) Sponsor
understands and acknowledges that the Company is entering into the Merger Agreement in reliance upon the Sponsor’s execution
and delivery of this Letter Agreement.

 

		5.	Sponsor hereby agrees to be bound by and subject to (i) Section 7.8 (Confidentiality; Communications
Plan; Access to Information) of the Merger Agreement to the same extent as such provisions apply to the parties to the Merger Agreement
as if Sponsor were a party thereto, and (ii) Section 7.2 (Parent No Solicitation) of the Merger Agreement to the same extent as
such provisions apply to Parent as if Sponsor were a party thereto.

 

		6.	The Company is an express third party beneficiary of this Letter Agreement entitled to the rights
and benefits hereunder and, solely in the event that there is a breach hereof by Sponsor that prevents the consummation of the
transactions contemplated by the Merger Agreement, shall be entitled to enforce the provisions hereof as if it was a party hereto.

 

		7.	This Letter Agreement, together with the Merger Agreement to the extent referenced herein, constitute
the entire agreement and understanding of the parties hereto in respect of the subject matter hereof and supersedes all prior understandings,
agreements, or representations by or among the parties hereto, written or oral, relating to the subject matter hereof.

 

		8.	No party hereto may assign either this Letter Agreement or any of its rights, interests, or obligations
hereunder without the prior written consent of the other party hereto, and any purported assignment in violation of the foregoing
shall be null and void ab initio. This Letter Agreement shall be binding on the parties hereto and their respective successors
and assigns.

 

		9.	This Letter Agreement shall be construed and interpreted in a manner consistent with the provisions
of the Merger Agreement. In the event of any conflict between the terms of this Letter Agreement and the Merger Agreement, the
terms of the Merger Agreement shall govern. The provisions set forth in Sections 10.1 (No Survival), 11.3 (Counterparts; Electronic
Delivery), 11.5 (Severability), 11.6 (Other Remedies; Specific Performance), 11.7 (Governing Law), 11.8 (Consent to Jurisdiction;
Waiver of Jury Trial), 11.12 (Amendment) and 11.13 (Extension; Waiver) of the Merger Agreement, as in effect as of the date hereof,
are hereby incorporated by reference into, and shall be deemed to apply to, this Letter Agreement mutatis mutandis.

 

		10.	Any notice, consent or request to be given in connection with any of the terms or provisions of
this Letter Agreement shall be in writing and shall be sent in the same manner as provided in the Merger Agreement, with (a) notices
to Parent being sent to the addresses set forth therein, in each case with all copies as required thereunder and (b) notices to
Sponsor being sent to:

 

Vector Acquisition Partners, L.P.

One Market Street

Steuart Tower, 23rd Floor

San Francisco, CA 94105

Attention:   Alex Slusky

E-mail:         alex@vectorcapital.com

 

    4

     

    

 

with a copy (which shall not constitute notice)
to:

 

Kirkland & Ellis LLP

609 Main Street

Houston, Texas 77002

Attention:   Debbie Yee, P.C.

                    Sean T. Wheeler, P.C.

                    Travis J. Distaso

E-mail:        debbie.yee@kirkland.com

                    sean.wheeler@kirkland.com

                    travis.distaso@kirkland.com

 

		11.	This Letter Agreement shall immediately and automatically terminate, and have no further force
and effect, upon the earlier of (i) the Effective Time or (ii) the termination of the Merger Agreement in accordance with its terms
prior to the Effective Time. Notwithstanding the foregoing or anything to the contrary in this Agreement, the termination of this
Agreement pursuant to this Section 11 shall not affect any liability on the part of any Party for a willful
breach of any covenant or agreement set forth in this Agreement prior to such termination or Actual Fraud, which liability shall
survive any termination of this Agreement. For purposes of this Section 11, “willful breach” means a material
breach that is a consequence of an act undertaken or a failure to act by the breaching party with the knowledge that the taking
of such act or such failure to act would, or would reasonably be expected to, constitute or result in a breach of this Letter Agreement.

 

[The remainder of this page left intentionally
blank.]

 

    5

     

    

 

Please indicate your
agreement to the terms of this Letter Agreement by signing where indicated below.

 

	 	Very truly yours,
	 	 	 
	 	Vector Acquisition Partners, L.P.
	 	 	 
	 	By: Vector Capital Partners V, L.P.,

its General Partner
	 	 	 
	 	By: Vector Capital Partners V, Ltd.,

its General Partner
	 	 	             
	 	By:	/s/ David Baylor
	 	Name: 	David Baylor
	 	Title:	Officer

 

	Acknowledged and agreed

 as of the date of this Letter Agreement:	 
	 	 	 
	Vector Acquisition Corporation	 
	 	 	 
	By:	/s/ David Baylor   	 
	Name: 	David Baylor	 
	Title:	Chief Financial Officer	 

 

Signature Page to Sponsor Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}]]